Table 2 Adjusted effectiveness of a ChAdOx1 against clinical Covid-19 outcomes in adults ≥60 years of age.
Symptomatic Covid-19 (n pairs = 30,680) | Covid-19 hospitalization (n pairs = 11,250) | ICU admission (n pairs = 4445) | Invasive mechanical ventilation (n pairs = 2672) | Covid-19-related death (n pairs = 4850) | |
|---|---|---|---|---|---|
Vaccine doses and timing | aVE (95% CI) | aVE (95% CI) | aVE (95% CI) | aVE (95% CI) | aVE (95% CI) |
Single dose, within 0–13 days vs. unvaccinated* | −7.1% (−19.6–4.1) | 13.1% (−4.4–27.7) | −9.1% (−46.6–18.8) | 12.7% (−29.2–41) | 16.1% (−11.9–37.2) |
Single dose, 14–27 days vs. unvaccinated* | 17.8% (8.0–26.5) | 33.6% (19.9–45.0) | 39.6% (15.4–56.8) | 51.8% (26.3–68.4) | 37.5% (15.2–54.0) |
Single dose, ≥28 days vs. unvaccinated* | 33.4% (26.4–39.7) | 55.1% (46.6–62.2) | 50.9% (33.6–63.8) | 70.5% (54.9–80.8) | 61.8% (48.9–71.4) |
Two doses, within 0–13 days vs. unvaccinated* | 38.1% (11.9–56.5) | 59.2% (32.4–75.4) | 50.9% (−41.8–83) | 75.2% (−18.7–94.8) | 77.8% (49.1–90.3) |
Two doses, ≥14 days vs. unvaccinated* | 77.9% (69.2–84.2) | 87.6% (78.2–92.9) | 89.9% (70.9–96.5) | 96.5% (81.7–99.3) | 93.6% (81.9–97.7) |
